Mr. Andre Larente reports

DIAGNOS ANNOUNCES CLOSING OF SECOND AND FINAL TRANCHE OF PRIVATE PLACEMENT

Diagnos Inc. has closed a second and final tranche of 650,000 units, issued at a price of 28 cents per unit for gross proceeds of $182,000, of a non-brokered private placement initially announced on Feb. 27, 2024. Combined with the first closing announced on Feb. 27, 2024, the aggregate number of units is 2,064,286 and the aggregate gross proceeds amount to $578,000.08.

Each unit consists of:

• One common share;
• One common share warrant.

As part of the closing of the second and final tranche of the private placement, 650,000 warrants have been issued to the subscribers. Each warrant can be exercised to purchase one share at a price of 40 cents per share for a period of 18 months ending Sept. 22, 2025. Combined with the first closing announced on Feb. 27, 2024, the aggregate number of warrants is 2,064,286.

The net proceeds from the private placement will be used to finance product development and commercialization of AI-based (artificial intelligence) screening services as well as general and administrative operations.

In connection with the closing of the second and final tranche of the private placement, the corporation: (i) paid cash commissions amounting to $7,840; and (ii) issued an aggregate number of 28,000 finder warrants to two qualified firms acting at arm's length. Each finder warrant entitles the finder to purchase one share at an exercise price of 40 cents per share for a period of 18 months ending Sept. 22, 2025.

All securities issued as part of the second and final tranche of the private placement are subject to a statutory hold period ending July 23, 2024.

The closing of the private placement remains subject to receipt of all required approvals, including the approval of the TSX Venture Exchange, as well as execution of formal documentation.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (computer-assisted retina analysis). CARA's image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients.

We seek Safe Harbor.